Siemens Healthcare, Roche Diagnostics Lead US Immunochemistry Market as Cardiovascular and Cancer Testing Becomes Prevalent

April 8, 2016 – Vancouver, BC – According to a new series of reports on the in-vitro diagnostics device market by iData Research (www.idataresearch.com), increasing immunoassay test volumes is the key driver of growth in the immunochemistry market. This can be attributed to the high prevalence of cardiovascular disorders and cancers among aging baby boomers coupled with unhealthy lifestyle choices. This aging demography suffering from chronic conditions and diseases coupled with the expansion of insured population through the implementation of health care reform will drive the demand for immunochemistry testing over the forecast period.

Immunochemistry testing is an integral part of modern health care practices due to increasing health awareness among people, strong emphasis by regulatory organizations on preventative care to contain costs and continuous technological advancements in this field. Testing is primarily performed in core laboratories of hospitals and in independent commercial labs. The immunochemistry market includes integrated, immunoassay, clinical chemistry and microscopy urinalysis analyzers, as well as reagents for immunoassay and clinical chemistry testing.

Nearly every hospital in the U.S. has a core lab with one or more of these analyzers. Most large hospitals have a backup unit in addition to their primary analyzer. The saturated market and high installed base have resulted in relatively stable unit sales from year to year. In addition, the instruments' lifespans have increased to an average of 8 years or more due to improved system durability and limited capital equipment budgets. Manufacturers typically enter into reagent rental contracts with large hospitals or reference labs to sell these systems.

As part of these contracts, manufacturers either provide the analyzers to the customers for free or charge them a substantially low price, while locking them into a binding agreement for the purchase of reagents over a period of 5 to 7 years. The cost of the analyzer is recovered through the sales of reagents. At the end of the contract, the analyzer is either returned back to the manufacturer or the contract is further extended. In some cases, the analyzer is sold to the customer at a lower price. Over 80% of the core lab analyzers are placed in large hospitals for the duration of these types of contracts. The remaining analyzers are purchased directly from either refurbished sellers or manufacturers.

"As the trend towards consolidation continues among hospitals, labs and other care facilities in order to provide efficient coordinated care at lower costs, demand for integrated systems capable of doing both immunoassays and chemistry testing at high throughput volumes is expected to increase," explains Dr. Kamran Zamanian, CEO of iData.

Fertility testing is another segment that promises growth. According to the Centers for Disease Control and Prevention (CDC), more than 7 million Americans, or approximately 12% of the population in their reproductive years, are infertile. As more women address fertility issues and are presented with different treatment options, the market for fertility immunoassay testing is expected to show continued growth over the forecast period.

The leading competitor in the immunochemistry market is Siemens Healthcare Diagnostics with nearly a 30% market share. Siemens gained a prominent position through their Dimension® line of analyzers, which can be customized to streamline workflow. Siemens also offers a line of reagents for use in their analyzers and systems. Siemens is one of the largest clinical diagnostics companies in the world with significant brand recognition, which helps encourage sales in the immunochemistry market, as labs can be fully furnished with Siemens products. Roche Diagnostics is the second leading competitor in the immunochemistry market with almost 20% market share. Their Cobas product line includes standalone immunoassay and clinical chemistry analyzers, as well as modular systems for immunochemistry. Other competitors in the immunochemistry market include Beckman Coulter, Abbott Diagnostics, Ortho, Clinical Diagnostics, and Sysmex America amongst others.

For Further Information
More on the immunochemistry market in United States can be found in a report suite published by iData Research entitled the US Market for In-Vitro Diagnostics Report Suite. The suite covers reports on the following markets: immunochemistry, molecular diagnostics, molecular blood donor screenings, hemostasis, hematology, and point of care diagnostic devices.

The report provides a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about immunochemistry market data or procedure data, register online or email us at info@idataresearch.net for a US Market for In-Vitro Diagnostics Report Suite brochure and synopsis.

About iData Research
iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.